Chitosan Oligosaccharide Alleviates Abnormal Glucose Metabolism without Inhibition of Hepatic Lipid Accumulation in a High-Fat Diet/Streptozotocin-Induced Diabetic Rat Model

This study investigated the effects of chitosan oligosaccharide (COS) on glucose metabolism and hepatic steatosis in a high-fat (HF) diet/streptozotocin-induced diabetic rat model. Male Wistar rats were divided into: (1) normal control (NC group), (2) HF diet (HF group), (3) streptozotocin (STZ)-ind...

Full description

Bibliographic Details
Main Authors: Shing-Hwa Liu, Fan-Wen Chen, Meng-Tsan Chiang
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Marine Drugs
Subjects:
Online Access:https://www.mdpi.com/1660-3397/19/7/360
_version_ 1797529056884817920
author Shing-Hwa Liu
Fan-Wen Chen
Meng-Tsan Chiang
author_facet Shing-Hwa Liu
Fan-Wen Chen
Meng-Tsan Chiang
author_sort Shing-Hwa Liu
collection DOAJ
description This study investigated the effects of chitosan oligosaccharide (COS) on glucose metabolism and hepatic steatosis in a high-fat (HF) diet/streptozotocin-induced diabetic rat model. Male Wistar rats were divided into: (1) normal control (NC group), (2) HF diet (HF group), (3) streptozotocin (STZ)-induced diabetes with HF diet (DF group), and DF group supplemented with (4) 0.5% COS (D0.5F group), (5) 1% COS (D1F group), and (6) 5% COS (D5F group) for 4 weeks. COS supplementation significantly decreased the plasma glucose, BUN, creatinine, uric acid, triglyceride (TG), and total cholesterol (TC) levels, and hepatic glucose-6-phosphatase activity, and significantly increased hepatic hexokinase activity and glycogen content in diabetic rats; but the increased hepatic TG and TC levels could not be significantly decreased by COS supplementation. Supplementation of COS increased superoxide dismutase activity and decreased lipid peroxidation products in the diabetic rat livers. COS supplementation significantly increased phosphorylated AMP-activated protein kinase (AMPK) protein expression, and attenuated protein expression of hepatic phosphoenolpyruvate carboxykinase (PEPCK) and phosphorylated p38 and renal sodium-glucose cotransporter-2 (SGLT2) in diabetic rats. These results suggest that COS may possess a potential for alleviating abnormal glucose metabolism in diabetic rats through the inhibition of hepatic gluconeogenesis and lipid peroxidation and renal SGLT2 expression.
first_indexed 2024-03-10T10:08:04Z
format Article
id doaj.art-f7e73c786b1e4f3ca5b22599a9a0a4ec
institution Directory Open Access Journal
issn 1660-3397
language English
last_indexed 2024-03-10T10:08:04Z
publishDate 2021-06-01
publisher MDPI AG
record_format Article
series Marine Drugs
spelling doaj.art-f7e73c786b1e4f3ca5b22599a9a0a4ec2023-11-22T01:27:28ZengMDPI AGMarine Drugs1660-33972021-06-0119736010.3390/md19070360Chitosan Oligosaccharide Alleviates Abnormal Glucose Metabolism without Inhibition of Hepatic Lipid Accumulation in a High-Fat Diet/Streptozotocin-Induced Diabetic Rat ModelShing-Hwa Liu0Fan-Wen Chen1Meng-Tsan Chiang2Graduate Institute of Toxicology, College of Medicine, National Taiwan University, Taipei 10051, TaiwanDepartment of Food Science, National Taiwan Ocean University, Keelung 20224, TaiwanDepartment of Food Science, National Taiwan Ocean University, Keelung 20224, TaiwanThis study investigated the effects of chitosan oligosaccharide (COS) on glucose metabolism and hepatic steatosis in a high-fat (HF) diet/streptozotocin-induced diabetic rat model. Male Wistar rats were divided into: (1) normal control (NC group), (2) HF diet (HF group), (3) streptozotocin (STZ)-induced diabetes with HF diet (DF group), and DF group supplemented with (4) 0.5% COS (D0.5F group), (5) 1% COS (D1F group), and (6) 5% COS (D5F group) for 4 weeks. COS supplementation significantly decreased the plasma glucose, BUN, creatinine, uric acid, triglyceride (TG), and total cholesterol (TC) levels, and hepatic glucose-6-phosphatase activity, and significantly increased hepatic hexokinase activity and glycogen content in diabetic rats; but the increased hepatic TG and TC levels could not be significantly decreased by COS supplementation. Supplementation of COS increased superoxide dismutase activity and decreased lipid peroxidation products in the diabetic rat livers. COS supplementation significantly increased phosphorylated AMP-activated protein kinase (AMPK) protein expression, and attenuated protein expression of hepatic phosphoenolpyruvate carboxykinase (PEPCK) and phosphorylated p38 and renal sodium-glucose cotransporter-2 (SGLT2) in diabetic rats. These results suggest that COS may possess a potential for alleviating abnormal glucose metabolism in diabetic rats through the inhibition of hepatic gluconeogenesis and lipid peroxidation and renal SGLT2 expression.https://www.mdpi.com/1660-3397/19/7/360chitosan oligosaccharideglucose metabolismdiabetes
spellingShingle Shing-Hwa Liu
Fan-Wen Chen
Meng-Tsan Chiang
Chitosan Oligosaccharide Alleviates Abnormal Glucose Metabolism without Inhibition of Hepatic Lipid Accumulation in a High-Fat Diet/Streptozotocin-Induced Diabetic Rat Model
Marine Drugs
chitosan oligosaccharide
glucose metabolism
diabetes
title Chitosan Oligosaccharide Alleviates Abnormal Glucose Metabolism without Inhibition of Hepatic Lipid Accumulation in a High-Fat Diet/Streptozotocin-Induced Diabetic Rat Model
title_full Chitosan Oligosaccharide Alleviates Abnormal Glucose Metabolism without Inhibition of Hepatic Lipid Accumulation in a High-Fat Diet/Streptozotocin-Induced Diabetic Rat Model
title_fullStr Chitosan Oligosaccharide Alleviates Abnormal Glucose Metabolism without Inhibition of Hepatic Lipid Accumulation in a High-Fat Diet/Streptozotocin-Induced Diabetic Rat Model
title_full_unstemmed Chitosan Oligosaccharide Alleviates Abnormal Glucose Metabolism without Inhibition of Hepatic Lipid Accumulation in a High-Fat Diet/Streptozotocin-Induced Diabetic Rat Model
title_short Chitosan Oligosaccharide Alleviates Abnormal Glucose Metabolism without Inhibition of Hepatic Lipid Accumulation in a High-Fat Diet/Streptozotocin-Induced Diabetic Rat Model
title_sort chitosan oligosaccharide alleviates abnormal glucose metabolism without inhibition of hepatic lipid accumulation in a high fat diet streptozotocin induced diabetic rat model
topic chitosan oligosaccharide
glucose metabolism
diabetes
url https://www.mdpi.com/1660-3397/19/7/360
work_keys_str_mv AT shinghwaliu chitosanoligosaccharidealleviatesabnormalglucosemetabolismwithoutinhibitionofhepaticlipidaccumulationinahighfatdietstreptozotocininduceddiabeticratmodel
AT fanwenchen chitosanoligosaccharidealleviatesabnormalglucosemetabolismwithoutinhibitionofhepaticlipidaccumulationinahighfatdietstreptozotocininduceddiabeticratmodel
AT mengtsanchiang chitosanoligosaccharidealleviatesabnormalglucosemetabolismwithoutinhibitionofhepaticlipidaccumulationinahighfatdietstreptozotocininduceddiabeticratmodel